MX2009012422A - Prevencion y tratamiento de afecciones del ojo asociadas con su complemento. - Google Patents

Prevencion y tratamiento de afecciones del ojo asociadas con su complemento.

Info

Publication number
MX2009012422A
MX2009012422A MX2009012422A MX2009012422A MX2009012422A MX 2009012422 A MX2009012422 A MX 2009012422A MX 2009012422 A MX2009012422 A MX 2009012422A MX 2009012422 A MX2009012422 A MX 2009012422A MX 2009012422 A MX2009012422 A MX 2009012422A
Authority
MX
Mexico
Prior art keywords
complement
prevention
treatment
eye conditions
associated eye
Prior art date
Application number
MX2009012422A
Other languages
English (en)
Spanish (es)
Inventor
Philip Hass
Christian Wiesmann
Menno Van Lookeren Campagne
Jianping Yin
Kenneth Katschke Jr
Micah Steffek
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009012422(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2009012422A publication Critical patent/MX2009012422A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
MX2009012422A 2007-05-23 2008-05-22 Prevencion y tratamiento de afecciones del ojo asociadas con su complemento. MX2009012422A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
PCT/US2008/064526 WO2008147883A1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Publications (1)

Publication Number Publication Date
MX2009012422A true MX2009012422A (es) 2009-12-04

Family

ID=39638868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012422A MX2009012422A (es) 2007-05-23 2008-05-22 Prevencion y tratamiento de afecciones del ojo asociadas con su complemento.

Country Status (28)

Country Link
US (6) US8007791B2 (enExample)
EP (1) EP2152755B1 (enExample)
JP (4) JP5416695B2 (enExample)
KR (1) KR101540126B1 (enExample)
CN (3) CN104367999A (enExample)
AR (1) AR066660A1 (enExample)
AU (1) AU2008256835B2 (enExample)
BR (1) BRPI0811142A8 (enExample)
CA (1) CA2683498A1 (enExample)
CL (1) CL2008001498A1 (enExample)
CY (1) CY1116062T1 (enExample)
DK (1) DK2152755T3 (enExample)
ES (1) ES2533242T3 (enExample)
HK (1) HK1207327A1 (enExample)
HR (1) HRP20150281T1 (enExample)
IL (2) IL201476A (enExample)
MX (1) MX2009012422A (enExample)
PE (1) PE20090294A1 (enExample)
PH (1) PH12013500992B1 (enExample)
PL (1) PL2152755T3 (enExample)
PT (1) PT2152755E (enExample)
RS (1) RS53901B1 (enExample)
RU (2) RU2522976C2 (enExample)
SG (1) SG10201401404RA (enExample)
SI (1) SI2152755T1 (enExample)
TW (2) TW201417829A (enExample)
WO (1) WO2008147883A1 (enExample)
ZA (1) ZA200907028B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
KR20150055628A (ko) 2005-11-04 2015-05-21 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
DK2097455T3 (en) * 2006-11-02 2014-12-15 Genentech Inc HUMANIZED ANTI-FACTOR D ANTIBODIES
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
BRPI0918496A2 (pt) * 2008-09-02 2019-09-24 Novartis Ag composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula
SG173167A1 (en) 2009-01-29 2011-08-29 Forsight Labs Llc Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
JP5907966B2 (ja) 2010-08-05 2016-04-26 フォーサイト・ビジョン フォー・インコーポレーテッド 埋め込み型治療デバイス
DK2635704T3 (en) 2010-11-01 2017-06-19 Hoffmann La Roche Predicting progression to advanced age-related macular degeneration using a polygenic score
BR112013017316A2 (pt) 2011-01-04 2019-09-24 Novartis Ag compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd)
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
JP6209605B2 (ja) 2012-06-28 2017-10-04 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
EP2867226B1 (en) 2012-06-28 2018-11-14 Novartis AG Complement pathway modulators and uses thereof
CN104640855B (zh) 2012-06-28 2017-08-29 诺华股份有限公司 补体途经调节剂及其用途
US9464081B2 (en) 2012-06-28 2016-10-11 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014009833A2 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
NZ731881A (en) 2012-07-25 2022-07-29 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
ES2972168T3 (es) 2013-03-28 2024-06-11 Forsight Vision4 Inc Implante oftálmico para administración de sustancias terapéuticas
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
WO2015054298A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
US20160339008A1 (en) * 2013-10-25 2016-11-24 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
MA39934A (fr) 2014-05-01 2017-03-08 Hoffmann La Roche Variants d'anticorps anti-facteur d et leurs utilisations
US10239943B2 (en) 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
WO2017053753A1 (en) * 2015-09-23 2017-03-30 Sangamo Biosciences, Inc. Htt repressors and uses thereof
MX395572B (es) 2015-10-30 2025-03-25 Genentech Inc Anticuerpos anti-htra1 y metodos de uso de los mismos
WO2017075252A1 (en) * 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
PL3368682T3 (pl) 2015-10-30 2020-05-18 F. Hoffmann-La Roche Ag Sposoby pomiaru aktywności czynnika D i siły działania inhibitorów czynnika D
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
HRP20211608T1 (hr) 2015-12-23 2022-01-21 eleva GmbH Polipeptidi za inhibiranje aktivacije komplementa
GB2553252B (en) * 2016-01-20 2019-07-31 Vitrisa Therapeutics Inc Aptamers that block the catalytic cleft of complement Factor D
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
IL268601B2 (en) 2017-02-10 2024-07-01 Univ Pennsylvania Anti-factor d antibodies and uses thereof
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
EP3999078A4 (en) * 2019-07-18 2023-06-14 Pandorum Technologies Private Limited METHODS FOR CULTURING MESENCHYMATOUS STEM CELLS, PRODUCTS RELATED AND THEIR APPLICATIONS

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2001004311A1 (en) 1999-07-07 2001-01-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999046281A2 (en) 1998-03-10 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
EP2014677A1 (en) 1997-11-21 2009-01-14 Genentech, Inc. A-33 related antigens and their pharmacological uses
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
EP1053245A4 (en) 1998-02-09 2002-04-17 Human Genome Sciences Inc 45 HUMAN SECRETED PROTEINS
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
EP1054693B8 (en) * 1998-02-20 2009-03-04 Genentech, Inc. Inhibitors of complement activation
EP1108019A2 (en) 1998-08-27 2001-06-20 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
KR100468977B1 (ko) 1998-12-16 2005-02-02 제넨테크, 인크. 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
ATE322909T1 (de) * 1998-12-21 2006-04-15 Ludwig Inst Cancer Res Antikörper gegen verkürzten vegf-d und deren verwendungen
EP1141284A2 (en) 1998-12-22 2001-10-10 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
AU3514400A (en) 1999-03-08 2000-09-28 Genentech Inc. Compositions and methods for the treatment of immune related diseases
EP2292761A1 (en) 1999-03-11 2011-03-09 Merck Serono S.A. Vascular adhesion molecules and modulation of their function
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
UA72943C2 (uk) 1999-11-02 2005-05-16 Ульяновскій Государствєнний Тєхніческій Унівєрсітєт Спосіб очищення рідини від феромагнітних частинок (варіанти) і пристрій для його здійснення (варіанти)
EP1234030A4 (en) 1999-11-19 2003-05-07 Human Genome Sciences Inc 18 HUMAN SECRETED PROTEINS
CA2490853A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040152105A1 (en) 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
KR20150055628A (ko) * 2005-11-04 2015-05-21 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
DK2097455T3 (en) * 2006-11-02 2014-12-15 Genentech Inc HUMANIZED ANTI-FACTOR D ANTIBODIES
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Also Published As

Publication number Publication date
CY1116062T1 (el) 2017-02-08
IL201476A0 (en) 2010-05-31
EP2152755B1 (en) 2014-12-31
IL201476A (en) 2016-11-30
AR066660A1 (es) 2009-09-02
BRPI0811142A8 (pt) 2018-12-18
EP2152755A1 (en) 2010-02-17
US8007791B2 (en) 2011-08-30
ES2533242T3 (es) 2015-04-08
TW200904471A (en) 2009-02-01
PH12013500992A1 (en) 2016-01-25
US8268310B2 (en) 2012-09-18
AU2008256835A1 (en) 2008-12-04
US20130302333A1 (en) 2013-11-14
CN104367999A (zh) 2015-02-25
DK2152755T3 (en) 2015-03-02
CN101754980B (zh) 2014-10-29
SI2152755T1 (sl) 2015-05-29
CN101754980A (zh) 2010-06-23
RU2522976C2 (ru) 2014-07-20
WO2008147883A1 (en) 2008-12-04
US20130052685A1 (en) 2013-02-28
PH12013500992B1 (en) 2018-12-14
CN107096029A (zh) 2017-08-29
TW201417829A (zh) 2014-05-16
PL2152755T3 (pl) 2015-06-30
WO2008147883A8 (en) 2013-05-23
SG10201401404RA (en) 2014-08-28
JP2010528047A (ja) 2010-08-19
JP5416695B2 (ja) 2014-02-12
RU2014113046A (ru) 2015-10-10
US8497094B2 (en) 2013-07-30
AU2008256835B2 (en) 2013-08-01
BRPI0811142A2 (pt) 2014-12-23
CA2683498A1 (en) 2008-12-04
CL2008001498A1 (es) 2009-06-12
PT2152755E (pt) 2015-04-01
JP2017197577A (ja) 2017-11-02
HRP20150281T1 (hr) 2015-04-10
HK1139161A1 (en) 2010-09-10
CN107096029B (zh) 2021-02-26
TWI419704B (zh) 2013-12-21
RS53901B1 (sr) 2015-08-31
US20090181017A1 (en) 2009-07-16
RU2009147744A (ru) 2011-06-27
ZA200907028B (en) 2010-12-29
US20110282034A1 (en) 2011-11-17
IL248552A0 (en) 2016-12-29
PE20090294A1 (es) 2009-03-27
US20180079826A1 (en) 2018-03-22
KR101540126B1 (ko) 2015-07-28
KR20100033973A (ko) 2010-03-31
HK1207327A1 (en) 2016-01-29
JP2016145205A (ja) 2016-08-12
US20160272726A1 (en) 2016-09-22
JP2014087346A (ja) 2014-05-15

Similar Documents

Publication Publication Date Title
MX2009012422A (es) Prevencion y tratamiento de afecciones del ojo asociadas con su complemento.
SG156649A1 (en) Crig polypeptide for prevention and treatment of complement-associated disorders
TN2013000275A1 (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
MY155320A (en) Alkoxy compounds for disease treatment
MY161495A (en) Virus like particle compositions and methods of use
MY171920A (en) Prevention and treatment of ocular conditions
WO2009129246A3 (en) Compositions and methods for preparing and using same
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
PH12013500577B1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
MX2010005115A (es) Anticuerpos anti-factor b y sus usos.
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
MX2010010303A (es) Nuevos compuestos de acido ribonucleico de pequeña interferencia para inhibir rtp801.
WO2014066799A3 (en) Modulators of resistant androgen receptor
WO2007133800A3 (en) Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
IN2012DN03361A (enExample)
HK1255695A1 (zh) 用於治疗眼睑下垂的组合物和方法
MX2016009600A (es) Agentes para utilizarse en el tratamiento de la inflamacion de retina.
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
HK1198514A1 (en) Substituted heterocyclic compounds for disease treatment
WO2007096745A8 (en) Methods for the treatment of macular degeneration and related eye conditions
HK1144291A (en) Anti-factor b antibodies and their uses
TW200744670A (en) Methods for the treatment of macular degeneration and related eye conditions
WO2012105854A3 (en) Compositions for administration to the eye

Legal Events

Date Code Title Description
FG Grant or registration